

PMR Public Report

Operation Number	BL-U0001	Chief of Operations Validation Date	11/08/21
Year- PMR Cycle	First period Jan-Jun 2021	Division Chief Validation Date	
Last Update	10/28/21	Country Representative Validation Date	
PMR Validation Stage	Validated by Chief of Operations		

Basic Data

Operation Profile

Operation Name	Support to the Financing of the Purchase of COVID-19 Vaccine and its Implementation	Loan Number	5234/OC-BL
Executing Agency	MINISTRY OF HEALTH	Sector/Subsector	HEALTH-DISEASE PREVENTION & CONTROL
Team Leader	AGUILAR RIVERA, ANA MYLENA	Overall Stage	Approved/Pending Signature
Operation Type	Guarantee	Country	Belize
Lending Instrument	Investment	Convergence related Operation(s)	
Borrower	BELIZE		

Environmental and Social Safeguards

Impacts Category	C	Was/Were the objective(s) of this operation reformulated?	NO
Safeguard Performance Rating		Date of approval	
Safeguard Performance Rating - Rationale			

Financial Data

Item	Total Cost and Source					Available Funds (US\$)			
	Original IDB	Current IDB	Local Counterpart	Co-Financing / Country	Total Original Cost	Current IDB	Disb. Amount to Date	% Disb	Undisbursed Amount
BL-U0001	2,137,260	2,137,260	0	0	2,137,260	2,137,260	0	0.00%	2,137,260
Aggregated	2,137,260	2,137,260	0	0	2,137,260	2,137,260	0	0.00%	2,137,260

Expense Categories by Loan Contract (cumulative values)

PMR Public Report

RESULTS MATRIX

General Development Objectives

General Development Objectives Nbr. 1: Contribute to the reduction of the morbidity and mortality caused by COVID-19 and to mitigate indirect impacts of the pandemic.

Observation: Baseline as of 16th of December 2020. The SIR model estimates a reduction of deaths with vaccine of 78% (3,605) and a reduction of cases of 78% with vaccine (192,000)

	Indicator	Unit of Measure	Baseline	Baseline Year	Expected Year of Achievement		Target
1.0	Number of deaths from COVID-19	Number	212.00	2020	2023	P	787.00
						A	
Details							
Pro-Gender	No			Pro-Ethnicity		No	
The General Development objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO)							
	No						
	Indicator	Unit of Measure	Baseline	Baseline Year	Expected Year of Achievement		Target
1.1	Confirmed cases of COVID-19	Number	9,672.00	2020	2023	P	42,000.00
						A	
Details							
Pro-Gender	No			Pro-Ethnicity		No	
The General Development objective indicator target is expected to be observed by the operation's "Fully Justified" date in Convergence (CO)							
	No						

PMR Public Report

RESULTS MATRIX

Specific Development Objectives

Specific Development Objectives Nbr. 1: Supporting initiatives to break the chain of transmission of the illness

Observation:

Indicator		Unit of Measure	Baseline	Baseline Year		2021	2022	2023	EOP 2036
1.0	Percentage of health personnel who have been vaccinated against COVID-19	Percentage	0.00	2020	P	100.00	0.00	0.00	100.00
					A				
Details									
Pro-Gender		No			Pro-Ethnicity		No		
Indicator		Unit of Measure	Baseline	Baseline Year		2021	2022	2023	EOP 2036
1.1	Percentage of people in vulnerable groups (elderly and chronic disease patients) who have been vaccinated against COVID-19	Percentage	0.00	2020	P	40.00	30.00	25.00	95.00
					A				
Details									
Pro-Gender		No			Pro-Ethnicity		No		

RESULTS MATRIX

OUTPUTS: ANNUAL PHYSICAL AND FINANCIAL PROGRESS

Component Nbr. 1 Component 1. Ensuring timely vaccine availability

				PHYSICAL PROGRESS		FINANCIAL PROGRESS	
	Output	Unit of Measure		2021	EOP 2036	2021	EOP 2036
1.1	Number of doses of COVID-19 vaccines procured	Number	P	95,520	238,800		
			P(a)	0	0		
			A		0		

CHANGES TO THE MATRIX

No information available for this section

IMPLEMENTATION STATUS AND LEARNING

No information available for this section